ARIAD Pharmaceuticals, Inc. Earnings Conference Call (Q1 2008)  Today's Calls

Visit the TF Network Sites· Corporate IR Center · Institutional Investor Center · Individual Investor Center Download Plug-In Real Player 8 Basic Windows Media Player Other Conference Calls Other May 7 Calls Today's Calls

Call Details ARIAD Pharmaceuticals, Inc. Earnings Conference Call (Q1 2008) Wed, May 7, 2008, 8:00 am Eastern Listen to the archived event audio About ARIAD Pharmaceuticals, Inc. (NasdaqGM:ARIA) ARIAD Pharmaceuticals, Inc., together with its subsidiaries, discovers and develops medicines to treat cancers by regulating cell signaling with small molecules in the United States and Europe. The company’s cancer product candidate includes deforolimus, a potent protein mTOR inhibitor for the treatment of solid tumors, such as sarcomas, hormone refractory prostate cancer, endometrial cancer, brain cancer, and leukemias and lymphomas. It offers Phase 3 clinical trial of oral deforolimus in patients with metastatic soft-tissue and bone sarcomas; and multiple clinical trials of deforolimus, including Phase 2 clinical trials in endometrial, breast, and prostate cancers. The company studies deforolimus as a single agent in multiple Phase 1 and Phase 2 clinical trials in patients with sarcomas, hormone refractory prostate cancer, endometrial cancer, brain cancer, and leukemias and lymphomas. It conducts various multi-center Phase 1b trials of deforolimus in combination with anti-cancer therapies, which focuses on patients with various types of solid tumors; and Phase 1 trials of AP24534 that is used in the treatment of drug-resistant and refractory chronic myeloid leukemia, and hematological cancers. The company licenses NF-kB cell-signaling technology and treatment methods to pharmaceutical and biotechnology companies that conducts research to discover and develop drugs that modulate NF-kB cell-signaling and/or marketing such drugs; and ARGENT cell-signaling regulation technology for various pharmaceutical and biotechnology companies for research and development of therapeutic vaccines, and gene and cell therapy. It has a license agreement with Medinol, Ltd. to develop and commercialize deforolimus-eluting stents and other medical devices to prevent restenosis or reblockage of injured vessels; and collaboration agreement with Merck & Co., Inc. to develop deforolimus. ARIAD Pharmaceuticals, Inc. was founded in 1991 and is based in Cambridge, Massachusetts. More Info: Quote | Chart | News | Profile | Reports | Research | SEC | Msgs | Insider | Financials | Analyst Ratings